Alx Oncology Holdings - Asset Resilience Ratio
Alx Oncology Holdings (ALXO) has an Asset Resilience Ratio of 60.58% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Alx Oncology Holdings to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Alx Oncology Holdings 's Asset Resilience Ratio has changed over time. See ALXO equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Alx Oncology Holdings 's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Alx Oncology Holdings market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $108.04 Million | 60.58% |
| Total Liquid Assets | $108.04 Million | 60.58% |
Asset Resilience Insights
- Very High Liquidity: Alx Oncology Holdings maintains exceptional liquid asset reserves at 60.58% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Alx Oncology Holdings Industry Peers by Asset Resilience Ratio
Compare Alx Oncology Holdings 's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Alx Oncology Holdings (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Alx Oncology Holdings .
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 48.13% | $28.42 Million | $59.05 Million | -26.44pp |
| 2024-12-31 | 74.57% | $110.19 Million | $147.78 Million | +8.47pp |
| 2023-12-31 | 66.10% | $160.33 Million | $242.55 Million | -4.83pp |
| 2022-12-31 | 70.93% | $217.38 Million | $306.49 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $380.18 Million | -- |
About Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collabora… Read more